EU Endorses New Measures to Protect Women From Valproate Epilepsy Drug EU Endorses New Measures to Protect Women From Valproate Epilepsy Drug

French regulator ANSM said epilepsy drug valproate would face new restrictions across the European Union to protect pregnant women or of child-bearing age from exposing their babies to possible malformations and developmental problems.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

Move follows recent high-profile cases of use of cannabis oil to curb frequency of epileptic fits in children Related items fromOnMedica Hunt announces Medicines and Medical Devices Safety Review Cannabis compound may help curb frequency of epileptic seizures Debate goes on over valproate in pregnancy MHRA tightens licence restrictions on valproate for women Stroke survivors need more help taking medicine
Source: OnMedica Latest News - Category: UK Health Source Type: news
PARIS (Reuters) - French regulator ANSM said epilepsy drug valproate would face new restrictions across the European Union to protect pregnant women or of child-bearing age from exposing their babies to possible malformations and developmental problems.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
PARIS (Reuters) - French regulator ANSM on Tuesday said Sanofi's epilepsy drug valproate should be forbidden during pregnancy and not prescribed to women of child-bearing age.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Authors: Andrade C Abstract Valproate and formulations thereof are approved for the management of seizure disorders, bipolar disorder, and migraine. Valproate is also used for many off-label indications. Unfortunately, data from observational studies indicate that valproate is perhaps the most teratogenic drug in the neuropsychiatric pharmacopeia. It is significantly more teratogenic than many other antiepileptic drugs (AEDs). In observational studies, gestational exposure to valproate is also associated with higher risks of cognitive, language, and psychomotor delay during early childhood and possibly with an incr...
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
Conclusion: Our study suggests that exposure to long-term prenatal stress results in increased susceptibility to seizures. PMID: 29853939 [PubMed]
Source: Korean Journal of Pediatrics - Category: Pediatrics Tags: Korean J Pediatr Source Type: research
Despite significant teratogenic risks, sodium valproate is still widely prescribed in many countries to women of childbearing age, as a mood stabiliser in bipolar disorder and also in epilepsy. The UK has rece...
Source: BMC Pregnancy and Childbirth - Category: OBGYN Authors: Tags: Debate Source Type: research
Acta Neurologica Scandinavica, EarlyView.
Source: Acta Neurologica Scandinavica - Category: Neurology Authors: Source Type: research
TRENTON, N.J. (AP) — U.S. regulators Thursday approved the first drug designed to prevent chronic migraines. The Food and Drug Administration’s action clears the monthly shot Aimovig for sale. It’s the first in a new class of long-acting drugs for preventing migraines. Three other shots are expected to win approval by next year, and several pills for preventing migraines are being tested. Current prevention treatments include pills originally developed for epilepsy and other conditions, and the wrinkle reducer Botox, but many patients abandon them because they don’t provide enough relief or cause se...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Local TV Migraines talkers Source Type: news
(TRENTON, N.J.) — U.S. regulators Thursday approved the first drug designed to prevent chronic migraines. The Food and Drug Administration’s action clears the monthly shot Aimovig (AIM’-oh-vig) for sale. It’s the first in a new class of long-acting drugs for preventing migraines. Three other shots are expected to win approval by next year, and several pills for preventing migraines are being tested.Current prevention treatments include pills originally developed for epilepsy and other conditions and the wrinkle reducer Botox, but many patients abandon them because they don’t help much or ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized onetime Pharmaceuticals Source Type: news
Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Source: Acta Obstetricia et Gynecologica Scandinavica - Category: OBGYN Authors: Source Type: research
More News: Babies | Brain | Child Development | Children | Epilepsy | France Health | Health | Neurology | Neurosurgery | Pregnancy | Women